{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:45:41Z","timestamp":1770745541852,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.clml.2020.07.006","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T12:33:22Z","timestamp":1594902802000},"page":"e956-e960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2245-4068","authenticated-orcid":false,"given":"Franco","family":"Castillo-Tokumori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chetasi","family":"Talati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najla","family":"Al Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-8233","authenticated-orcid":false,"given":"David","family":"Sallman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seongseok","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendra","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Lancet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew T.","family":"Kuykendall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.07.006_bib1","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kr\u00f6ger","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.07.006_bib2","first-page":"1","article-title":"Myelofibrosis treatment algorithm, 2018","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2020.07.006_bib3","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A\u00a0pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.07.006_bib4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.4065\/79.7.883","article-title":"Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia","volume":"79","author":"Mesa","year":"2004","journal-title":"Mayo Clinic Proc"},{"key":"10.1016\/j.clml.2020.07.006_bib5","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3904\/kjim.2018.033","article-title":"Recent advances in the diagnosis and management of primary myelofibrosis","volume":"33","author":"Takenaka","year":"2018","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.clml.2020.07.006_bib6","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1182\/blood-2010-05-287417","article-title":"Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903","volume":"116","author":"Mesa","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.07.006_bib7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/leu.2016.300","article-title":"A\u00a0randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence","volume":"31","author":"Tefferi","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.07.006_bib8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2010-12-325589","article-title":"Comparison of thalidomide and lenalidomide as therapy for myelofibrosis","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.07.006_bib9","first-page":"1058","article-title":"Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.1016\/j.clml.2020.07.006_bib10","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2019-127661","article-title":"Safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: a phase II study","volume":"134","author":"Rampal","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.07.006_bib11","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.07.006_bib12","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.07.006_bib13","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group\u2013Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.07.006_bib14","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","article-title":"Lenalidomide therapy in myelofibrosis with myeloid metaplasia","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.07.006_bib15","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/cncr.21827","article-title":"Thalidomide therapy for myelofibrosis with myeloid metaplasia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.07.006_bib16","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/leu.2016.299","article-title":"Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis","volume":"31","author":"Schlenk","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.07.006_bib17","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.leukres.2014.06.015","article-title":"Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia","volume":"38","author":"Daver","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2020.07.006_bib18","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","article-title":"A\u00a0phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia","volume":"101","author":"Mesa","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.07.006_bib19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s11899-018-0447-9","article-title":"Management of myelofibrosis-related cytopenias","volume":"13","author":"Bose","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2020.07.006_bib20","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/s41375-018-0078-0","article-title":"U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.07.006_bib21","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(14)00026-X","article-title":"Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1\/2 study","volume":"2","author":"DiNardo","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2020.07.006_bib22","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.07.006_bib23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ajh.25610","article-title":"Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation","volume":"95","author":"Abou Dalle","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.07.006_bib24","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ccell.2015.03.017","article-title":"Inherited and somatic defects in DDX41 in myeloid neoplasms","volume":"27","author":"Polprasert","year":"2015","journal-title":"Cancer Cell"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020303402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020303402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:51Z","timestamp":1761870891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020303402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S2152265020303402"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.07.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}